Projet HYPERBOOST (Horizon 2020, appel à projets 2020)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Hyperthermia (HT), heating tumors to temperatures of 40-44°C, is an oncological treatment used in combination with radiotherapy (RT) and chemotherapy to enhance their efficacy. Clinical effectiveness of HT has been demonstrated in randomised studies and HT is currently applied for many clinical indications, like cervical cancer and recurrent breast cancer. Clinical results can be further improved as application of HT with well-controlled tumor temperatures and optimal timing and sequence realising full synergy of RT+HT is challenging. Optimal HT delivery requires accurate planning, moreover preclinical research has shown that many mechanisms are responsible for the therapeutic effect of HT, all presumably with a different temperature-effect relationship and with different optimal timing between RT and HT. Optimisation of clinical RT+HT treatments therefore requires a quantum leap in understanding and in clinical application. Scientific objective of this multidisciplinary project with contributions from all sectors and disciplines (biology, physics and oncology) is to combine training and research into the synergistic molecular mechanisms responsible for the therapeutic effect of HT on RT with the development of a versatile and innovative planning platform which utilises biological knowledge to achieve optimal patient-specific treatment delivery and ultimately application in a clinical registration study in a network of European centres implementing this treatment planning software to ensure optimal treatment delivery. This ground-breaking and multidisciplinary project with contributions from biology, physics and oncology will create a versatile and innovative planning platform, enhance fundamental knowledge and create practical tools to achieve personalised treatment, thereby augmenting treatment delivery and clinical results. The projects will also educate 15 highly skilled professionals capable of addressing and solving complex oncological issues.

Mots clés : hyperthermia, treatment planning, personalised medicine

Participants :
- Universitätsklinikum Erlangen (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 505576.8 €
- Amsterdam University Medical Centers (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 531239.76 €
- University of Zurich (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281276.64 €
- Zürcher Fachhochschule (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281276.64 €
- Chalmers University of Technology (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281982.96 €
- Aarhus University (Danemark) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 595044.0 €
- Charité - Universitätsmedizin Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Med-logix societa a responsabilita limitata (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 261499.68 €
- Max Delbrück Center for Molecular Medicine (Allemagne) — Partner, beneficiary, Recherche, subvention : 252788.4 €
- Dr sennewald medizintechnik gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 252788.4 €
- Erasmus MC (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265619.88 €